1. Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis
- Author
-
Martina Catalano, Alberto Pesci, Marco Sebastiani, Andreina Teresa Manfredi, Paola Faverio, Elena Bargagli, Carlo Salvarani, Marco Confalonieri, Francesco Salton, Giulia Dei, Lorenzo Cavagna, Maria Rosa Pozzi, Paolo Cameli, Paola Rebora, Fabrizio Luppi, Dei, Giulia, Rebora, Paola, Catalano, Martina, Sebastiani, Marco, Faverio, Paola, Rosa Pozzi, Maria, Manfredi, Andreina, Cameli, Paolo, Salton, Francesco, Salvarani, Carlo, Cavagna, Lorenzo, Confalonieri, Marco, Bargagli, Elena, Luppi, Fabrizio, Pesci, Alberto, Dei, G, Rebora, P, Catalano, M, Sebastiani, M, Faverio, P, Pozzi, M, Manfredi, A, Cameli, P, Salton, F, Salvarani, C, Cavagna, L, Confalonieri, M, Bargagli, E, Luppi, F, and Pesci, A
- Subjects
interstitial lung disease ,antisynthetase syndrome ,lung function ,autoantibodies antisynthetase ,anti-Jo-1 antibodies ,no anti-Jo-1 antibodies ,medicine.medical_specialty ,Population ,lcsh:Medicine ,Antisynthetase syndrome ,Gastroenterology ,Article ,Pulmonary function testing ,Serology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Outpatient clinic ,Respiratory function ,education ,030203 arthritis & rheumatology ,education.field_of_study ,Lung ,anti-Jo-1 antibodie ,business.industry ,lcsh:R ,Interstitial lung disease ,General Medicine ,medicine.disease ,medicine.anatomical_structure ,030228 respiratory system ,business - Abstract
Antisynthetase syndrome (ASSD) is a rare autoimmune disease characterized by serologic positivity for antisynthetase antibodies. Anti-Jo1 is the most frequent, followed by anti PL-7, anti PL-12, anti EJ, and anti OJ antibodies. The lung is the most frequently affected organ, usually manifesting with an interstitial lung disease (ILD), which is considered the main determinant of prognosis. Some evidences suggest that non-anti-Jo-1 antibodies may be associated with more severe lung involvement and possibly with poorer outcomes, while other authors do not highlight differences between anti-Jo1 and other antisynthetase antibodies. In a multicenter, retrospective, &ldquo, real life&rdquo, study, we compared lung function tests (LFTs) progression in patients with ILD associated with anti-Jo1 and non-anti-Jo1 anti-synthetase antibodies to assess differences in lung function decline between these two groups. Therefore, we analyzed a population of 57 patients (56% anti-Jo1 positive), referred to the outpatient Clinic of four referral Centers in Italy (Modena, Monza, Siena, and Trieste) from 2008 to 2019, with a median follow-up of 36 months. At diagnosis, patients showed a mild ventilatory impairment and experienced an improvement of respiratory function during treatment. We did not observe statistically significant differences in LFTs at baseline or during follow-up between the two groups. Moreover, there were no differences in demographic data, respiratory symptoms onset (acute vs. chronic), extrapulmonary involvement, treatment (steroid and/or another immunosuppressant), or oxygen supplementation. Our study highlights the absence of differences in pulmonary functional progression between patients positive to anti-Jo-1 vs. non anti-Jo-1 antibodies, suggesting that the type of autoantibody detected in the framework of ASSD does not affect lung function decline.
- Published
- 2020